Screening of a heptamer-type sgRNA library for potential therapeutic agents against hematological malignancies.

[1]  J. Mattick,et al.  Long noncoding RNAs and the genetics of cancer , 2013, British Journal of Cancer.

[2]  Tetsuo Yoshida,et al.  Induction of apoptosis of leukemic cells by TRUE gene silencing using small guide RNAs targeting the WT1 mRNA. , 2013, Leukemia research.

[3]  C. Norbury,et al.  The Long and Short of MicroRNA , 2013, Cell.

[4]  Tetsuo Yoshida,et al.  A naked RNA heptamer targeting the human Bcl-2 mRNA induces apoptosis of HL60 leukemia cells. , 2013, Cancer letters.

[5]  M. Kaminski,et al.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.

[6]  C. Koch.  Modular Biological Complexity , 2012, Science.

[7]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[8]  Tetsuo Yoshida,et al.  Elimination of Specific miRNAs by Naked 14-nt sgRNAs , 2012, PloS one.

[9]  M. Tamura,et al.  Expanding the utility of heptamer-type sgRNA for TRUE gene silencing. , 2011, Biochemical and biophysical research communications.

[10]  N. Munshi,et al.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.

[11]  A. Nagler,et al.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.

[12]  Y. Sasaguri,et al.  Dopamine Induces IL-6–Dependent IL-17 Production via D1-Like Receptor on CD4 Naive T Cells and D1-Like Receptor Antagonist SCH-23390 Inhibits Cartilage Destruction in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model , 2011, The Journal of Immunology.

[13]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[14]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[15]  M. Nashimoto,et al.  Human cytosolic tRNase ZL can downregulate gene expression through miRNA , 2009, FEBS letters.

[16]  Masayuki Nashimoto,et al.  Modulation of Gene Expression by Human Cytosolic tRNase ZL through 5′-Half-tRNA , 2009, PloS one.

[17]  M. Tamura,et al.  Inhibition of vascular endothelial growth factor expression by TRUE gene silencing. , 2009, Biochemical and biophysical research communications.

[18]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[19]  S. Landais,et al.  Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. , 2007, Cancer research.

[20]  M. Nashimoto,et al.  The T Loop Structure Is Dispensable for Substrate Recognition by tRNase ZL* , 2005, Journal of Biological Chemistry.

[21]  N. Miyano-Kurosaki,et al.  Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL , 2005, Nucleic acids research.

[22]  Masato Tamura,et al.  Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers. , 2003, Nucleic acids research.

[23]  M. Nashimoto,et al.  A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. , 2003, Nucleic acids research.

[24]  M. Nashimoto.  Anomalous RNA substrates for mammalian tRNA 3′ processing endoribonuclease , 2000, FEBS letters.

[25]  Masayuki Nashimoto,et al.  RNA heptamers that direct RNA cleavage by mammalian tRNA 3' processing endoribonuclease. , 1998, Nucleic acids research.

[26]  M. Nashimoto.  Specific cleavage of target RNAs from HIV-1 with 5' half tRNA by mammalian tRNA 3' processing endoribonuclease. , 1996, RNA.

[27]  M. Nashimoto,et al.  Conversion of mammalian tRNA 3' processing endoribonuclease to four-base-recognizing RNA cutters. , 1995, Nucleic acids research.

[28]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Miyamoto,et al.  Establishment and characterization of a human myeloma cell line (KMM‐1) , 1982, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[30]  S. Collins,et al.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia , 1979 .

[31]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[32]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[33]  G. Moore,et al.  Production of Free Light Chains of Immunoglobulin by a Hematopoietic Cell Line Derived from a Patient with Multiple Myeloma.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  J. T. Syverton,et al.  STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES , 1953, The Journal of experimental medicine.

[35]  J. T. Syverton,et al.  STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES , 1952, The Journal of experimental medicine.

[36]  Kevin V. Morris,et al.  RNA and the regulation of gene expression : a hidden layer of complexity , 2008 .

[37]  M. Tamura,et al.  Gene silencing by the tRNA maturase tRNase ZL under the direction of small-guide RNA , 2007, Gene Therapy.

[38]  M. Nashimoto,et al.  A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules. , 2004, Nucleic acids research.

[39]  M. Nashimoto,et al.  The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity. , 2004, Nucleic acids research.

[40]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.